Assessing the combined Impact of Interventions on the HIV and Syphilis epidemics among gbMSM in British Columbia: a co-interaction model


> Jummy David, Fred Brauer, Jielin Zhu, and Viviane D. Lima (17 October 2019)

Background and Objectives:

- The population of gay, bisexual and other men who have sex with men (gbMSM) remain the most affected by HIV infection in British Columbia (BC)
- □ Majority of infectious syphilis cases (over 80% of all cases) in BC were among gbMSM
- Currently, HIV Treatment as Prevention (TasP), Condom use, and Pre-Exposure Prophylaxis (PrEP) have been highly effective for HIV prevention and control in gbMSM
- Similarly, Condom use, Test&Treat diagnosed cases of syphilis have also been effective
- This study assesses how the combination of TasP, Condom use, PrEP, and Test & Treat syphilis can be used to prevent/eliminate further HIV-syphilis transmission and co-interaction among the gbMSM population in BC

We developed a mathematical model of the co-interaction of HIV/syphilis transmission and progression among gbMSM in BC

We developed a mathematical model of the co-interaction of HIV/syphilis transmission and progression among gbMSM in BC



Deterministic model of HIV-syphilis co-interaction

Modeling the force of HIV/syphilis infection

$$\lambda_{S} = \beta_{S}(1 - \epsilon\xi)((1 - \psi) + \psi R_{P})\frac{(I_{S} + \phi_{1}U_{SH} + \phi_{2}A_{SH} + \phi_{3}T_{SH})}{N}$$

$$\lambda_{H} = \beta_{H}(1 - \epsilon\xi)((1 - \psi) + (1 - \theta)\psi R_{P})\frac{(U_{H} + \kappa_{1}A_{H} + \kappa_{2}U_{SH} + \kappa_{3}A_{SH})}{N}$$

□ The transmission parameters were fitted and calibrated on:

- Public Health Agency of Canada (PHAC) estimates of HIV incidence and Prevalence for gbMSM in BC,
- Annual HIV diagnoses from HIV Cascade of Care in British Columbia Centre for Excellence in HIV/AIDS (BC-CfE), and
 - Annual syphilis diagnoses from British Columbia Centre for Disease Control

□ We studied the impact of optimizing:

- > TasP
- Test & Treat syphilis,
- Condom use
- ➢ PrEP.

TasP:

decreasing the time to HIV diagnosis

- decreasing time to antiretroviral (ART) treatment
- ✓ increasing the time retained on ART

Test & Treat syphilis:

decreasing the time from syphilis infection to treatment

- We measure the impact of intervention at the end of 10 years (from 2019 until 2028) on:
- > HIV point prevalence and incident cases
- All-cause mortality cases among PLWH
- syphilis incident cases
- WHO threshold for disease elimination: <1 HIV and/or syphilis new case per 1000 susceptible gbMSM</p>
- univariate sensitivity coefficients for HIV and syphilis incidence changes under three PrEP uptake scenarios at the end of 2028
- Percent change in the number of cumulative HIV and syphilis incident cases with respect to the Status Quo scenario from 2019 to 2028

Intervention scenarios:

• TasP:

- Status Quo: based on model calibration
- Intervention:
 - Low: test every 2years, treat within 3months and retain on treatment for atleast 3.5years
 - Medium: test every year, treat within 45 days and retain on treatment for atleast 4.5 years
 - High: test every 6months, treat within 21days and retain on treatment for atleast 6years

• **PrEP**:

- Status Quo: 4000
- Intervention: linearly increase to maximum PrEP uptake in 2028
- Low: 5000; Medium: 7000; High: 10,000

• **Condom use(%)**:

- Status Quo: 65
- Intervention: linearly increase to maximum condom use in 2028
- Low: 70; Medium: 75; High: 80

• Test & Treat Syphilis:

- Status Quo: based on model calibration
- Intervention (mono-infected individuals):
 - Low: test & treat within 2years
 - Medium: test & treat 8months
 - **High**: test & treat **3**months
- Intervention (co-infected individuals):
 - Low: test & treat within **10**years
 - **Medium**: test & treat **5**years
 - **High**: test & treat **3**years


Model outcomes:

Reduction in HIV point prevalence, incident cases, and all-cause mortality cases (left), and syphilis incident cases (right), among gbMSM after 10 years of TasP, PrEP, condom use, and Test & Treat (syphilis) interventions



Model outcomes:

Univariate Sensitivity Analysis on HIV incidence (left column) and syphilis incidence (right column) for various PrEP strategies



Model outcomes:

Sensitivity Analysis on HIV incidence (left column) and syphilis incidence (right column) for the top 10 parameters with the most uncertainty

Time from HIV infection	5 yr			I
to diagnosis $1/\alpha_1$ (3.37 yr.) Higher risk of HIV transmission	3 mo.			
	4.0			
coinfected aware κ_3 (2.0) Higher risk of HIV transmission	1.0			
	4.0			
coinfected unaware κ_2 (2.0) Higher risk of HIV transmission	1.0			
	2.0			
Time to treatment drop out	0.8			
	10 yr.			
coinfected $1/\nu_2$ (2.72 yr.) Proportion of condoms	18.0 mo.			
	95%.			
ϵ (65%) Effectiveness of condoms	35%.			
	95%.			
ξ (70%) Time from syphilis infection to treatment	55%.			
	20 yr			
coinfected $1/\sigma_2$ (18.6 yr.) Time to ART initiation	1 yr			
	14.0 dy.			
coinfected $1/\rho_1$ (4.61 mo.) Transmission rate, HIV	7 mo.			
	0.25			
infection β_H (0.195)	0.05			
	25	%	0%	25%
		Increase in HIV inc		Decrease in HIV incidence

Higher risk of HIV transmission coinfected aware κ_3 (2.0)	4.0				1			
	1.0							
Higher risk of HIV transmission coinfected unaware κ_2 (2.0)	4.0							
	1.0							
Higher risk of HIV transmission monoinfected aware κ_1 (1.0) Proportion of condoms ϵ (65%)	2.0							
	0.8							
	95%.							
	35%.							
Effectiveness of condoms ξ (70%)	95%.							
	55%.							
Time from syphilis infection to treatment	20 yr							
coinfected $1/\sigma_2$ (18.6 yr.)	1 yr							
Time to ART initiation coinfected $1/\rho_1$ (4.61 mo.)	14.0 dy.							
	7 mo.							
Transmission rate, syphilis infection β_{S} (0.234)	0.35							
	0.15							
Transmission rate, HIV infection β_H (0.195)	0.25							
	0.05							
Natural mortality rate μ (0.0084 per PY)	0.005/PY							
	0.015/PY				1			
	25		00		25%			
Increase in syphilis incidence Decrease in syphilis incidence								

WHO Threshold for HIV Elimination

(<1 new HIV case per 1000 susceptible gbMSM):

WHO Threshold for Disease Elimination 4.5 Low HIV INCIDENCE PER 1000 SUSCEPTIBLE GBMSM 4.01 3.88 4 Medium 3.62 3.49 High 3.5 3.26 3.17 3.07 3.03 3 2.8 2.63 2.5 2.35 2.15 2.04 1.97 1.91 1.89 2 1.73 1.71 1.71 1.66 1.52 .5 1.5 1 0.66 0.61 0.53 0.49 0.46 0.41 0.5 0.2 0.15 0.17 0.14 0.13 0.11 0 Combined Combined Condom TasP, and TasP and Test & TasP, Test PrEP Use TasP and Test & TasP, Test Status Quo in TasP Test & Use Test & Condom Treat & Treat PrEP Use Treat & Treat, 2028 Treat syphilis, syphilis, syphilis, and PrEP Treat Use and PrEP syphilis syphilis and and Use Condom Condom Use Use Use

INTERVENTION SCENARIOS

WHO Threshold for syphilis Elimination

(<1 new syphilis case per 1000 susceptible gbMSM):

WHO Threshold for Disease Elimination 30 SYPHILIS INCIDENCE PER 1000 SUSCEPTIBLE GBMSM 25.94 25.31 24.89 Low 24.68 25 23.61 22.98.2 23.39 Medium 22 27.76 21.2 🔳 High 20.21 20 18.13 16.67 15.43 14.39 15 14.27 14.02 14.02 14.15 12.3 12.14 10 4.58 4.47 4.43 4.55 5 3.41 3.43 1.32 1.31 1.25 1.26 0.85 0.86 0

INTERVENTION SCENARIOS

TasP and

Condom

Use

Test &

Treat

syphilis,

and

Condom

Use

Combined Combined

Test &

Treat

syphilis

TasP

Status Quo in

2028

Condom

Use

TasP, and

Test &

Treat

syphilis

PrEP Use

TasP and

PrEP Use

Test &

Treat

syphilis,

and PrEP

Use

TasP, Test

& Treat

syphilis,

and

Condom

Use

TasP, Test

& Treat.

and PrEP

Use

Summary:

Optimizing TasP, Test&Treat syphilis, and increased provision of PrEP resulted in about 88% reduction in HIV incidence, and HIV incident rate as low as 0.13 per 1000 susceptible gbMSM

Optimizing Test&Treat syphilis, and increased proportion of condom use resulted in about 80% reduction in syphilis incidence, and syphilis incident rate as low as 0.85 per 1000 susceptible gbMSM

Optimizing TasP, Test&Treat syphilis, combined with condom use resulted in HIV & syphilis incident rate as low as 0.11 & 0.86 respectively and elimination of both diseases was possible

Only TasP significantly decreased mortality while PrEP increased syphilis incidence by about 5%

Conclusions:

 Optimizing TasP, through promotion of timely HIV diagnosis, treatment initiation and higher retention, and improving time from syphilis infection to treatment, combined with the distribution of PrEP was the most successful strategy to control the HIV epidemic

 Optimizing Test & Treat syphilis, and increased condom use was the most successful strategy to control the syphilis epidemic

Frequent testing of syphilis and other STIs, particularly among gbMSM using PrEP should be prioritized to control the syphilis epidemic

 Consistent use of condoms should continue to be encouraged and promoted to simultaneously reduce HIV and syphilis transmission particularly among those who may not be eligible for PrEP

Appreciation:

- Fred Brauer: Supervisor
- Viviane D. Lima: Co-supervisor
- Priscilla E. Greenwood: Committee member
- Daniel Coombs: Informal Graduate Advisor
- Jielin Zhu: Collaborator

Thank you!